Q3 EPS Estimates for Zimmer Biomet Lowered by Roth Capital

Key Points

• Roth Capital has lowered its Q3 2025 earnings per share estimate for Zimmer Biomet from $1.90 to $1.89, while maintaining a "Buy" rating on the stock.
• Recent analyses by various institutions have resulted in significant drops in price objectives for Zimmer Biomet, with Goldman Sachs reducing its target from $120.00 to $104.00.
• Zimmer Biomet reported a quarterly EPS of $2.07 for the latest quarter, exceeding the consensus estimate of $1.98, along with a revenue of $2.08 billion.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Investment analysts at Roth Capital decreased their Q3 2025 earnings per share estimates for shares of Zimmer Biomet in a research note issued to investors on Thursday, August 7th. Roth Capital analyst J. Wittes now anticipates that the medical equipment provider will earn $1.89 per share for the quarter, down from their previous estimate of $1.90. Roth Capital has a "Buy" rating on the stock. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share. Roth Capital also issued estimates for Zimmer Biomet's Q4 2025 earnings at $2.15 EPS, Q1 2026 earnings at $1.85 EPS, Q2 2026 earnings at $2.24 EPS, Q3 2026 earnings at $2.01 EPS, Q4 2026 earnings at $2.55 EPS and FY2026 earnings at $8.66 EPS.

Other equities analysts have also recently issued reports about the stock. The Goldman Sachs Group decreased their price objective on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price objective on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. Robert W. Baird decreased their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company decreased their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, Evercore ISI decreased their price objective on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $111.44.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $99.14 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a 50-day moving average of $93.34 and a two-hundred day moving average of $99.65. The stock has a market cap of $19.64 billion, a P/E ratio of 24.12, a PEG ratio of 2.28 and a beta of 0.68. Zimmer Biomet has a 1-year low of $89.22 and a 1-year high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.01 EPS.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were issued a $0.24 dividend. The ex-dividend date of this dividend was Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet's dividend payout ratio (DPR) is currently 23.36%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider owned 20,424 shares of the company's stock, valued at $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of large investors have recently bought and sold shares of the business. Alberta Investment Management Corp bought a new position in Zimmer Biomet in the second quarter worth about $1,286,000. Creative Planning lifted its holdings in Zimmer Biomet by 24.1% in the second quarter. Creative Planning now owns 31,445 shares of the medical equipment provider's stock worth $2,868,000 after acquiring an additional 6,105 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Zimmer Biomet by 6.6% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 48,523 shares of the medical equipment provider's stock valued at $4,426,000 after purchasing an additional 2,997 shares during the period. Sittner & Nelson LLC raised its holdings in shares of Zimmer Biomet by 20.8% during the second quarter. Sittner & Nelson LLC now owns 2,575 shares of the medical equipment provider's stock valued at $235,000 after buying an additional 443 shares during the last quarter. Finally, ABN Amro Investment Solutions acquired a new position in shares of Zimmer Biomet during the second quarter worth approximately $3,181,000. Institutional investors own 88.89% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.